Lucinda Billingham

6PUBLICATIONS
39CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Neurology and neuromuscular diseasesPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 09, 2026
Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.

|Jun 18, 2026
The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial.

|Feb 26, 2025
Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial.

Renuka P Dias, Kristian Brock, Kun Hu

|Nov 15, 2022
Protocol for the Tessa Jowell BRAIN MATRIX Platform Study.

Colin Watts, Joshua Savage, Amit Patel

|Mar 05, 2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.

Tobias Menne, Daniel Slade, Joshua Savage

|Jul 12, 2021
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).

Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell

Pageof 1

Frequent Collaborators

3 joint publications

Joshua Savage

2 joint publications

Gary Middleton

1 joint publications

Colin Watts

1 joint publications

Susan Mollan